HLA-A*24:02 increase the risk of allopurinol-induced drug reaction with eosinophilia and systemic symptoms in HLA-B*58:01 carriers in a Korean population; a multicenter cross-sectional case-control study
© 2022 The Authors. Clinical and Translational Allergy published by John Wiley and Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology..
Background: HLA-B*58:01 is a well-known risk factor for allopurinol-induced severe cutaneous adverse reactions (SCARs). However, only a minority of HLA-B*58:01 carriers suffer SCARs after taking allopurinol. The aim of this study was to investigate subsidiary genetic markers that could identify those at further increased risk of developing allopurinol-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in subjects with HLA-B*58:01.
Methods: Subjects with B*58:01 were enrolled (21 allopurinol-induced DRESS and 52 allopurinol-tolerant control). HLA-A, -B, -C and -DRB1 alleles were compared. Comparison of risk between HLAs and allopurinol-induced SCAR in separate populations was performed to support the results. Kruskal-Wallis test, Pearson's chi-square test, Fisher's exact test and binary logistic regression were used to analyze the risk of SCAR development.
Results: Frequencies of A*24:02 (71.4 vs. 17.3%, p < 0.001, odds ratio [OR] = 12.0; 95% confidence interval [CI], 3.6-39.2) were significantly higher in B*58:01 (+) DRESS than B*58:01 (+) tolerant controls. In addition, DRB1*13:02 further increased the risk of DRESS. The phenotype frequency of A*24:02/DRB1*13:02 was significantly higher in the B*58:01 (+) DRESS group than in the B*58:01 (+) tolerant controls (52.4% vs. 5.8%, p < 0.001, OR, 66.0; 95% CI, 6.1-716.2). In 2782 allopurinol user cohort, the overall prevalence of DRESS was 0.22%, which increased to 1.62% and 2.86% in the presence of B*58:01 and B*58:01/A*24:02, respectively.
Conclusion: The additional secondary screening with A*24:02 and DRB1*13:02 alleles may identify those at further increased risk of allopurinol-induced DRESS in B*58:01 carriers.
| Errataetall: |
ErratumIn: Clin Transl Allergy. 2024 Apr;14(4):e12351. - PMID 38578246 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Clinical and translational allergy - 12(2022), 9 vom: 26. Sept., Seite e12193 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Mi-Yeong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allopurinol |
|---|
| Anmerkungen: |
Date Revised 05.04.2024 published: Electronic-eCollection ErratumIn: Clin Transl Allergy. 2024 Apr;14(4):e12351. - PMID 38578246 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/clt2.12193 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346922704 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346922704 | ||
| 003 | DE-627 | ||
| 005 | 20240405232951.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/clt2.12193 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM346922704 | ||
| 035 | |a (NLM)36176736 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Mi-Yeong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HLA-A*24:02 increase the risk of allopurinol-induced drug reaction with eosinophilia and systemic symptoms in HLA-B*58:01 carriers in a Korean population; a multicenter cross-sectional case-control study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a ErratumIn: Clin Transl Allergy. 2024 Apr;14(4):e12351. - PMID 38578246 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Authors. Clinical and Translational Allergy published by John Wiley and Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. | ||
| 520 | |a Background: HLA-B*58:01 is a well-known risk factor for allopurinol-induced severe cutaneous adverse reactions (SCARs). However, only a minority of HLA-B*58:01 carriers suffer SCARs after taking allopurinol. The aim of this study was to investigate subsidiary genetic markers that could identify those at further increased risk of developing allopurinol-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in subjects with HLA-B*58:01 | ||
| 520 | |a Methods: Subjects with B*58:01 were enrolled (21 allopurinol-induced DRESS and 52 allopurinol-tolerant control). HLA-A, -B, -C and -DRB1 alleles were compared. Comparison of risk between HLAs and allopurinol-induced SCAR in separate populations was performed to support the results. Kruskal-Wallis test, Pearson's chi-square test, Fisher's exact test and binary logistic regression were used to analyze the risk of SCAR development | ||
| 520 | |a Results: Frequencies of A*24:02 (71.4 vs. 17.3%, p < 0.001, odds ratio [OR] = 12.0; 95% confidence interval [CI], 3.6-39.2) were significantly higher in B*58:01 (+) DRESS than B*58:01 (+) tolerant controls. In addition, DRB1*13:02 further increased the risk of DRESS. The phenotype frequency of A*24:02/DRB1*13:02 was significantly higher in the B*58:01 (+) DRESS group than in the B*58:01 (+) tolerant controls (52.4% vs. 5.8%, p < 0.001, OR, 66.0; 95% CI, 6.1-716.2). In 2782 allopurinol user cohort, the overall prevalence of DRESS was 0.22%, which increased to 1.62% and 2.86% in the presence of B*58:01 and B*58:01/A*24:02, respectively | ||
| 520 | |a Conclusion: The additional secondary screening with A*24:02 and DRB1*13:02 alleles may identify those at further increased risk of allopurinol-induced DRESS in B*58:01 carriers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HLA‐A24 antigen | |
| 650 | 4 | |a Koreans | |
| 650 | 4 | |a allopurinol | |
| 650 | 4 | |a drug hypersensitivity syndrome | |
| 650 | 4 | |a histocompatibility antigens class I | |
| 700 | 1 | |a Yun, James |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Dong-Yoon |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Tae Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Min-Kyung |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sunggun |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Min-Gyu |e verfasserin |4 aut | |
| 700 | 1 | |a Nam, Young-Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Jeong-Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Min-Suk |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Seung Seok |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Hajeong |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Hyun-Jai |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jaeseok |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Kook-Hwan |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Yon Su |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Jae Woo |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Kye Hwa |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Hye-Ryun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational allergy |d 2011 |g 12(2022), 9 vom: 26. Sept., Seite e12193 |w (DE-627)NLM216124530 |x 2045-7022 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:9 |g day:26 |g month:09 |g pages:e12193 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/clt2.12193 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 9 |b 26 |c 09 |h e12193 | ||